1. Home
  2. ENTX vs GNSS Comparison

ENTX vs GNSS Comparison

Compare ENTX & GNSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • GNSS
  • Stock Information
  • Founded
  • ENTX 2010
  • GNSS 1992
  • Country
  • ENTX Israel
  • GNSS United States
  • Employees
  • ENTX N/A
  • GNSS N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • GNSS Consumer Electronics/Appliances
  • Sector
  • ENTX Health Care
  • GNSS Consumer Staples
  • Exchange
  • ENTX Nasdaq
  • GNSS Nasdaq
  • Market Cap
  • ENTX 86.3M
  • GNSS 78.1M
  • IPO Year
  • ENTX 2018
  • GNSS N/A
  • Fundamental
  • Price
  • ENTX $2.01
  • GNSS $2.03
  • Analyst Decision
  • ENTX Strong Buy
  • GNSS Strong Buy
  • Analyst Count
  • ENTX 1
  • GNSS 3
  • Target Price
  • ENTX $10.00
  • GNSS $5.33
  • AVG Volume (30 Days)
  • ENTX 66.0K
  • GNSS 140.4K
  • Earning Date
  • ENTX 11-07-2025
  • GNSS 08-14-2025
  • Dividend Yield
  • ENTX N/A
  • GNSS N/A
  • EPS Growth
  • ENTX N/A
  • GNSS N/A
  • EPS
  • ENTX N/A
  • GNSS N/A
  • Revenue
  • ENTX $166,000.00
  • GNSS $30,470,000.00
  • Revenue This Year
  • ENTX N/A
  • GNSS $90.97
  • Revenue Next Year
  • ENTX N/A
  • GNSS $75.75
  • P/E Ratio
  • ENTX N/A
  • GNSS N/A
  • Revenue Growth
  • ENTX 191.23
  • GNSS 8.95
  • 52 Week Low
  • ENTX $1.50
  • GNSS $1.46
  • 52 Week High
  • ENTX $2.79
  • GNSS $4.04
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 52.55
  • GNSS 62.48
  • Support Level
  • ENTX $2.00
  • GNSS $1.84
  • Resistance Level
  • ENTX $2.22
  • GNSS $2.17
  • Average True Range (ATR)
  • ENTX 0.11
  • GNSS 0.13
  • MACD
  • ENTX 0.01
  • GNSS 0.02
  • Stochastic Oscillator
  • ENTX 50.00
  • GNSS 62.86

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About GNSS Genasys Inc.

Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.

Share on Social Networks: